glp 1 gip gcg Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature LY3437943, a novel triple glucagon,

The study results, published in the July 15, 2026, online edition of The Lancet Gastroenterology & Hepatology , address a major unmet need for people with metabolic dysfunctionassociated steatohepatitis (MASH), a serious form of fatty liver disease that can lead to cirrhosis, liver failure, and the need for transplantation

When low-and-slow dosing (or staying at the starting dose) makes sense and why not everyone needs aggressive escalation

Discuss a taper plan and safety monitoring with your clinician

Per week: 2 swabs 8 weeks: 16 swabs 12 weeks: 24 swabs 16 weeks: 32 swabs 20 weeks: 40 swabs recommend 1 100-count box Protocol Overview Concise summary of the once-weekly regimen